Did the market overreact to Biogen’s Alzheimer’s data?
Biogen’s recently soaring stock price can be attributed to investor optimism in one of the most stubborn areas of drug development.
Drug Development
Former FDA commissioner Califf to pharma: opening up on health data requires overcoming risk
Califf spoke about the importance of more data to faster and cheaper drug development at the NewYorkBIO conference.
The infectious disease doctor mining the microbiome for drugs
How Seres CEO Roger Pomerantz went from an infectious disease doctor to mining the microbiome for drugs.
Has DTC in the oncology space kept up with science?
As oncology drugs save or extend the lives of many more patients than anyone could have imagined a few years ago, a new challenge has emerged in the wake of their approval: Selling them to patients scared about their prognosis and alternately ignorant of and skeptical about recent breakthroughs in treatment.
Five things for pharma marketers to know: Wednesday, February 21, 2018
AbbVie reports successful elagolix trial; White House touts short-term insurance plans; Mayo Clinic chief to retire.
Five things for pharma marketers to know: Wednesday, February 14, 2018
IPG 2017 net income drops; Bristol-Myers Squibb inks $1.85 billion deal with Nektar on cancer drug; Merck halts final-stage Alzheimer’s drug.
New tactics change clinical trial awareness game
Recruitment for clinical trials has never been easy. New tools and tactics could change that — assuming the sheer volume of information doesn’t overwhelm trial organizers.
Five things for pharma marketers to know: Thursday, January 11, 2018
Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations
Five things for pharma marketers to know: Friday, December 8, 2017
FDA approves first nebulized LAMA COPD treatment; more than 2,000 cancer immunotherapies in development; FDA issues 3D-printing guidance
First ‘Digital Drug’ Faces a Second Litmus Test: Improving Adherence
Technology like this could expand further to form better collaborations between pharma, payers and organized providers.
